Rituximab and ABVD for Hodgkin's Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 31, 2001

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions
Lymphoma
Interventions
DRUG

Rituximab

375 mg/m\^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.

DRUG

Adriamycin

25 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Bleomycin

10 U/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Vinblastine

6 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

DRUG

Dacarbazine (DTIC)

375 mg/m\^2 injected by vein over 3 hours every other week for a total of 12 treatments.

Trial Locations (1)

77030

UT MD . Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER